PGT-A stands for preimplantation genetic testing for aneuploidy. It is done during IVF to check embryos for missing or extra chromosomes before an embryo is transferred to the uterus. The goal is not to test for every genetic disease, but to help identify embryos that are more likely to implant and continue as a healthy pregnancy.

PGT-A is generally considered when the chance of chromosomal errors is higher, such as in women of advanced maternal age, couples with recurrent pregnancy loss, or people with repeated IVF failures. It is an add-on to IVF, not a replacement for IVF. A fertility specialist and embryology team review whether the expected benefit is worth the cost, time, and the fact that some embryos may not be suitable for transfer after testing.

PGT-A is most often considered for patients with a higher risk of aneuploid embryos or a history suggesting embryo-related losses. Common indications include age-related infertility, recurrent miscarriage, repeated unsuccessful IVF cycles, and a prior pregnancy with a chromosomal condition. It may also be discussed when many embryos are expected and the couple wants to prioritize the embryo with the best chromosomal profile.

• Women typically above 35 years, especially above 37-38 years
• Recurrent pregnancy loss after excluding other causes
• Repeated failed embryo transfers or implantation failure
• Severe male factor infertility in select cases
• Couples with a family history of chromosomal problems after genetic counselling

It is not automatically recommended for every IVF patient, because its value depends on age, embryo number, and clinical history.

PGT-A is performed only within an IVF cycle. First, eggs are retrieved and fertilized in the laboratory. The embryos are grown to the blastocyst stage, usually day 5 or day 6, because this is the stage when biopsy is most commonly done. A few cells are taken from the outer trophectoderm layer of the embryo, which forms the placenta, and sent to a genetics laboratory for chromosome analysis.

The embryos are usually frozen while the report is awaited, and then a suitable embryo is selected for frozen embryo transfer in a later cycle. The result helps classify embryos as likely euploid, aneuploid, or sometimes mosaic, depending on the testing platform and reporting standards. Counseling before and after testing is important so the couple understands what the report can and cannot tell them.

When used in the right patient, PGT-A can improve embryo selection by identifying embryos with a normal chromosome count, which may increase the chance of implantation per transfer. It may also reduce the risk of miscarriage caused by chromosomal abnormalities and can lower the emotional and financial burden of repeated failed transfers.

For some patients, PGT-A can shorten the time to pregnancy by helping the team choose the embryo most likely to succeed first. This can be valuable when there are multiple embryos and a limited window of time due to age or other fertility factors. However, the benefit is not universal. In younger patients with fewer embryos, the incremental advantage may be small, so individualized decision-making is essential.

PGT-A is generally safe for the embryo when performed by an experienced embryology team, but it is still an invasive lab procedure and not risk-free. The embryo biopsy itself has a small technical risk, and not every embryo will survive freezing and thawing perfectly. A major limitation is that the test is a screening tool, not an absolute diagnosis.

• Embryos may be labeled mosaic or inconclusive
• Some embryos can be discarded or not transferred based on results
• False positive or false negative results can occur, though uncommon
• The process adds cost and may increase cycle length

Because embryo testing cannot guarantee a live birth, couples should also be counselled about prenatal testing options in pregnancy, especially if a transfer is successful.

There is no single success rate for PGT-A in India because outcomes depend heavily on maternal age, embryo quality, lab standards, the number of embryos tested, and whether the couple has recurrent miscarriage or repeated IVF failure. In typical Indian IVF practice, the main value of PGT-A is often seen as a higher implantation chance per transfer and a lower miscarriage risk in selected patients, rather than a guaranteed increase in cumulative live birth for every couple.

As a realistic range, clinics may see better per-transfer pregnancy outcomes in selected patients with good-quality euploid embryos, while younger women with limited embryos may not see much added benefit. Success is usually strongest when the indication is correct, the IVF lab is strong, and the genetics report is interpreted by an experienced team. Indian couples should ask for age-specific counselling rather than generic success claims.

The cost of PGT-A in India usually depends on the IVF package, the number of embryos biopsied, the genetic testing platform used, and whether freezing and later frozen transfer are included. In many Indian metro centres, the extra PGT-A cost over IVF commonly falls in the range of INR 1.5 lakh to INR 3.5 lakh, though some cases may be lower or higher depending on the laboratory and embryo count.

Always confirm whether the quoted price includes medicines, biopsy, lab fees, freezing, and transfer.

HomeIVF helps couples navigate PGT-A with clearer counselling, coordinated appointments, and a smoother IVF journey from testing to transfer. For many Indian patients, the biggest challenge is not just the procedure itself but understanding whether PGT-A is truly appropriate, what the report means, and how much it will cost end to end. Home IVF supports that decision-making with physician-led guidance and transparent planning.

With Home IVF, patients can discuss eligibility, timing, and next steps without unnecessary confusion. The team can coordinate investigations, fertility specialist review, embryo transfer planning, and follow-up, reducing missed visits and delays. For couples who live outside major metro areas or need privacy and convenience, Home IVF can make high-quality fertility care more accessible while keeping the medical pathway evidence-based and individualized.